Dose Dense Carboplatin, Taxotere and Herceptin As Primary Systemic Therapy in Breast Cancer

Completed · Phase 2

Conditions studied: Breast Cancer

In brief

Dose dense therapy has been shown to increase survival in the adjuvant setting of breast cancer. It is unknown if dose dense therapy will improve survival in tumors that express her-2. This study evaluates a neoadjuvant regimen containing carboplatin, taxotere and herceptin when used in a dose dense manner in patients with large breast cancers. The endpoint of pathologic complete response is used as a surrogate marker for survival.

Key facts

Study ID

NCT00232479

Run by

University of Miami

People needed

48

Starts

2005-09-01

Expected to finish

2008-06-01

Last updated by the study team

2012-08-21

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• HER-2 overexpressing breast cancer
• Clinical stage 2-3B
• Normal ejection fraction

You may not qualify if…

• Metastatic disease
• Low ejection fraction

Where it is running

• Jackson Memorial Hospital — Miami, Florida, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.